We used the available information on tumor stage at diagnosis, grade of tumor differentiation, and hormone receptor status as potential surrogates for treatment, since these characteristics are strong determinants of the therapeutic strategy, at least in most settings where the EPIC cohorts were recruited. The gene discussed is NR4A1; the disease is neoplasm.